1. Home
  2. STTK vs EROK Comparison

STTK vs EROK Comparison

Compare STTK & EROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Shattuck Labs Inc.

STTK

Shattuck Labs Inc.

BUY

Current Price

$5.65

Market Cap

652.4M

Sector

Health Care

ML Signal

BUY

Logo EagleRock Land LLC Class A shares representing limited liability company interests

EROK

EagleRock Land LLC Class A shares representing limited liability company interests

N/A

Current Price

$21.76

Market Cap

623.3M

Sector

Energy

ML Signal

N/A

Company Overview

Basic Information
Metric
STTK
EROK
Founded
2016
2023
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Oil & Gas Production
Sector
Health Care
Energy
Exchange
Nasdaq
Nasdaq
Market Cap
652.4M
623.3M
IPO Year
2020
2026

Fundamental Metrics

Financial Performance
Metric
STTK
EROK
Price
$5.65
$21.76
Analyst Decision
Strong Buy
Buy
Analyst Count
11
6
Target Price
$15.22
★ $28.83
AVG Volume (30 Days)
★ 1.1M
152.7K
Earning Date
11-05-2026
11-19-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 53.02
N/A
EPS
N/A
★ N/A
Revenue
★ $1,000,000.00
N/A
Revenue This Year
N/A
$154.84
Revenue Next Year
N/A
$17.21
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$1.70
$20.06
52 Week High
$8.33
$27.42

Technical Indicators

Market Signals
Indicator
STTK
EROK
Relative Strength Index (RSI) 35.85 40.27
Support Level $3.55 $20.13
Resistance Level $7.83 $22.53
Average True Range (ATR) 0.46 0.99
MACD -0.01 -0.10
Stochastic Oscillator 5.65 38.19

Price Performance

Historical Comparison
STTK
EROK

About STTK Shattuck Labs Inc.

Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.

About EROK EagleRock Land LLC Class A shares representing limited liability company interests

EagleRock Land LLC is a surface-focused land management company, focused on providing access to land, resources, and infrastructure assets in the Permian Basin, including areas in Texas and New Mexico. Its assets support oil and natural gas development, as well as activities related to power generation, water infrastructure, and other industries. Through its land position and integrated infrastructure assets, the company generates revenue and royalties from completion and production-based activities, including surface damages, ROWs, easements, commercial water supply and produced water recycling, handling and disposal and other surface and subsurface related activities.

Share on Social Networks: